GlaxoSmithKline reports positive data from Arzerra clinical trial

GlaxoSmithKline has announced data from a new clinical trial of its leukaemia drug Arzerra, which reflect the product’s safety and efficacy.

The company, in association with partner Genmab, recently concluded a pivotal trial of the treatment which gauged its efficacy among patients with fludarabine and alemtuzumab refractory chronic lymphocytic leukaemia.

It was found that the monoclonal antibody-based treatment demonstrated levels of activity which were consistent with GlaxoSmithKline’s previous interim analysis, thereby proving the treatment’s overall efficacy.

In addition, no unexpected safety issues were highlighted by the study.

Arzerra is planned for launch in the EU soon, with the European Commission having granted a conditional marketing authorisation to the drug in April this year, while it has also received accelerated approval from the US Food and Drug Administration.

Earlier this week, GlaxoSmithKline was given a recommendation for regulatory clearance of Arixtra, which would become Europe’s first superficial vein thrombosis treatment.